Instrument Inactif

Communiqués Paratek Pharmaceuticals, Inc.

Actions

PRTK

US6993743029

Produits pharmaceutiques

Communiqués

05/10/23	Healthcare & Life Sciences Private Equity Deal Tracker: Gurnet Point And Novo Holdings Acquire Paratek Pharmaceuticals	AQ
05/10/23	Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023	AQ
21/09/23	Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.	AQ
18/09/23	Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/S	AQ
12/09/23	Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/S	AQ
07/09/23	Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings	GL
09/08/23	Investor Alert: Abbott Cooper PLLC Announces Investigation into Paratek Pharmaceuticals, Inc.; Urges Paratek Stockholders to Contact Abbott Cooper Regarding Their Legal Rights	BU
03/08/23	Paratek: Q2 Earnings Snapshot	AQ
03/08/23	Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 Million	AQ
02/08/23	Paratek Pharmaceuticals Files Definitive Proxy Statement and Letter to Stockholders in Connection with Acquisition by Gurnet Point Capital and Novo Holdings	AQ
11/07/23	NexPoint Sends Demand Letter for Books and Records to Paratek Pharmaceuticals in Connection with Proposed Acquisition by Gurnet Point Capital	PR
10/07/23	Paratek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax	AQ
27/06/23	Paratek Pharmaceuticals Acknowledges Receipt of NexPoint Letter	AQ
27/06/23	European Medicines Agency COMP Recommends Positive Opinion on Orphan Medicinal Product Designation for NUZYRA® (omadacycline) for Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease	AQ
20/06/23	PRTK Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Paratek Pharmaceuticals to Gurnet Point Capital and Novo Holdings	AQ
12/06/23	Paratek Pharmaceuticals Presenting New Data from NUZYRA® (omadacycline) and Investigator-Initiated Research Programs at ASM Microbe 2023	AQ
07/06/23	PARATEK PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
06/06/23	Paratek Pharmaceuticals to be Acquired by Gurnet Point Capital and Novo Holdings	AQ
09/05/23	Paratek: Q1 Earnings Snapshot	AQ
09/05/23	Paratek Pharmaceuticals Announces First Quarter 2023 Revenue of $31.2 Million	AQ
01/05/23	Paratek Pharmaceuticals to Report Financial Results for First Quarter 2023 on May 9	AQ
10/04/23	Paratek Pharmaceuticals Presenting New Data from NUZYRA® (omadacycline) and Investigator-Initiated Research Programs at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2023	AQ
16/03/23	Paratek Pharmaceuticals : Corporate Presentation - Spring 2023	PU
16/03/23	PARATEK PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	AQ
16/03/23	Paratek Pharmaceuticals Announces Full-Year 2022 Revenue of $160.3 Million	AQ